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The incidence of obesity has risen dramati-
cally over the last few decades. Although most
attention has focused on high caloric diet and
sedentary lifestyle as the root causes, the role
of environmental factors is gaining credence.
Animal studies suggest that in utero or lifetime
exposure to xenobiotic chemicals can alter the
programming of metabolic homeostasis
(Heindel 2003; Newbold et al. 2007). Such
chemicals also affect glucose and lipid metabo-
lism as well as adipogenesis in murine
adipocytes (Alonso-Magdalena et al. 2006;
Masuno et al. 2005). To support the claim
that endocrine disruptors may increase the
risk of developing obesity-associated disorders,
it is critically important to examine their
effects on human adipose tissue.
Adiponectin is an adipocyte-speciﬁc hor-
mone that protects against metabolic syn-
drome (Kadowaki et al. 2006). This syndrome
is defined by a cluster of conditions that
include abdominal obesity, glucose intoler-
ance, hyperinsulinemia, hypertriglyceremia,
and hypertension and is associated with
increased risk of diabetes and cardiovascular
disease (Ritchie and Connell 2007). Serum
adiponectin levels are reduced before develop-
ment of type 2 diabetes, are lower in obese
than in lean individuals, and increase after
weight loss (Trujillo and Scherer 2005).
Because adiponectin is a critical adipokine
that increases insulin sensitivity and reduces
tissue inflammation (Whitehead et al.
2006), any factor that suppresses its release
could lead to insulin resistance and increased
susceptibility to development of metabolic
syndrome.
Bisphenol A (BPA), a monomer of poly-
carbonate plastics, is one of the highest-volume
chemicals in commerce. Polycarbonates are
used in numerous consumer products,
including food and water containers, baby
bottles, linings of metal food and beverage
cans, medical tubing, epoxy resins, and dental
fillings. Small amounts of BPA can migrate
from polymers to food or water, especially
when heated (Le et al. 2008). Dozen of stud-
ies have documented widespread human
exposure to BPA. Levels of BPA ranging from
0.3 to 5 ng/mL (~ 1–20 nM) are present in
adult and fetal human plasma, urine, and
breast milk (reviewed by Welshons et al.
2006). BPA, a lipophilic compound, can
accumulate in fat, with detectable levels
found in 50% of breast adipose tissue samples
from women (Fernandez et al. 2007).
BPA has been reported to alter several
metabolic functions (Alonso-Magdalena et al.
2005, 2006; Masuno et al. 2005; Sakurai
et al. 2004). However, a major issue relates to
the micromolar doses of BPA used in some of
these studies. Until BPA is proven active at
environmentally relevant concentrations (the
low nanomolar range), it is not certain that it
poses risks to human health. Moreover, BPA
often exhibits a lack of linear dose-dependent
relationship, showing instead U-shaped or
inverted U-shaped curves. Consequently,
extrapolation from an action, or lack of
action, of BPA at high doses to its presumed
bioactivity at low doses is unwarranted.
The mechanism by which BPA exerts its
biological actions is enigmatic. Although BPA
binds both estrogen receptors (ERs) α and β
(Kuiper et al. 1998), its binding affinity is
several orders of magnitude lower than that of
estradiol (E2), suggesting that it should mimic
or compete with endogenous estrogens only
at the micromolar range. Yet, BPA at
nanomolar doses often displays stronger
estrogen-like activities than E2 itself. Several
speculations have been proposed to reconcile
this discrepancy: a) BPA binds differently
within the ligand-binding domain of ERα or
ERβ and recruits dissimilar coregulators (Safe
et al. 2002); b) BPA elicits rapid responses by
binding to membrane-anchored ERs (Watson
et al. 2005), an as-yet-unidentified non-
classical membrane ER (ncmER; Alonso-
Magdalena et al. 2005), or G-protein–
coupled receptor 30 (GPR30; Thomas and
Dong 2006); and c) BPA binds to estrogen-
related receptor γ (ERRγ), an orphan nuclear
receptor belonging to the ERR family of
receptors that do not directly bind E2 (Ariazi
and Jordan 2006). BPA was recently reported
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BACKGROUND: The incidence of obesity has risen dramatically over the last few decades. This
epidemic may be affected by exposure to xenobiotic chemicals. Bisphenol A (BPA), an endocrine
disruptor, is detectable at nanomolar levels in human serum worldwide. Adiponectin is an
adipocyte-speciﬁc hormone that increases insulin sensitivity and reduces tissue inﬂammation. Thus,
any factor that suppresses adiponectin release could lead to insulin resistance and increased suscep-
tibility to obesity-associated diseases.
OBJECTIVES: In this study we aimed to compare a) the effects of low doses of BPA and estradiol
(E2) on adiponectin secretion from human breast, subcutaneous, and visceral adipose explants and
mature adipocytes, and b) expression of putative estrogen and estrogen-related receptors (ERRs) in
these tissues.
METHODS: We determined adiponectin levels in conditioned media from adipose explants or
adipocytes by enzyme-linked immunosorbant assay. We determined expression of estrogen receptors
(ERs) α and β, G-protein–coupled receptor 30 (GPR30), and ERRs α, β, and γ by quantitative real-
time polymerase chain reaction.
RESULTS: BPA at 0.1 and 1 nM doses suppressed adiponectin release from all adipose depots exam-
ined. Despite substantial variability among patients, BPA was as effective, and often more effective,
than equimolar concentrations of E2. Adipose tissue expresses similar mRNA levels of ERα, ERβ,
and ERRγ, and 20- to 30-fold lower levels of GPR30, ERRα, and ERRβ.
CONCLUSIONS: BPA at environmentally relevant doses inhibits the release of a key adipokine that
protects humans from metabolic syndrome. The mechanism by which BPA suppresses adiponectin
and the receptors involved remains to be determined.
KEY WORDS: adipocytes, adiponectin, bisphenol A, estradiol, estrogen receptors, estrogen-related
receptors, human adipose explants, obesity. Environ Health Perspect 116:1642–1647 (2008).
doi:10.1289/ehp.11537 available via http://dx.doi.org/ [Online 14 August 2008]to bind at high afﬁnity to ERRγ (Okada et al.
2008).
The objectives of the present study were to
a) compare the effects of low doses of BPA and
E2 on adiponectin secretion from human
breast, subcutaneous (SC), and visceral (VIS)
adipose explants; b) examine whether they
exert direct effects on isolated mature
adipocytes; c) determine the effects of an
ERα/ERβ antagonist [ICI182,780 (ICI)] on
adiponectin release; and d) compare the expres-
sion of ERα, ERβ, GPR30, ERRα, ERRβ, and
ERRγ in breast, SC, and VIS adipose tissue.
Materials and Methods
Subjects. The study was approved by the
Institutional Review Board of Christ Hospital
(Cincinnati, Ohio). Surgical samples were
obtained from patients who gave written
informed consent. Three types of adipose speci-
mens were obtained: a) samples from breast
reduction, b) abdominal SC samples from
abdominoplasty, and c) matched VIS (omental)
and SC samples from morbidly obese individu-
als undergoing gastric bypass surgery.
Explant preparation and incubation. We
cut tissue into small (~ 2 × 2 × 2 mm) explants
and placed them into 48-well polystyrene
plates (70–100 mg/250 µL, four to six wells
per treatment) containing glucose- and phenol
red-free Dulbecco’s modified Eagle medium
supplemented with 10 mM HEPES, 2 mM
glutamine, 2 mM pyruvate, and 1% charcoal-
stripped fetal bovine serum (Hyclone, Logan,
UT). We prepared stock solutions of E2 and
BPA (Sigma, St. Louis, MO; purity > 99%)
and ICI (Tocris, Ellisville, MO) in ethanol at
50–100 mM. Solvent controls (≤ 0.001%
ethanol) were included in all experiments. At
the end of a 6-hr incubation, explant weights
were determined and conditioned media (CM)
were collected.
Cell harvesting and incubation. We used
SC adipose tissue from abdominoplasty to
prepare mature adipocytes as described by
McFarland-Mancini et al. (2006). Brieﬂy, we
placed tissue fragments into Hank’s balanced
salt solution containing 2% fatty-acid–free
bovine serum albumin (BSA) and 200 nM
adenosine (to prevent cell rupture). After
adding 200 units/g of type IV collagenase
(Worthington, Lakewood, MO), we carried
out digestion at 37°C. The digest was ﬁltered
through a 150-µm mesh and the floating
mature adipocytes were separated from the
stromal vascular fraction by centrifugation.
Adipocytes (100 µL of packed cells) were
placed in wide-mouth polypropylene tubes
and incubated for 6 hr in the above media
containing the various treatments.
Adiponectin enzyme-linked immuno-
sorbant assay (ELISA). Adiponectin in CM
was quantified by a fluorescent-sandwich
ELISA, optimized in our laboratory using a
matched monoclonal antibody pair against
human adiponectin (MAB10651 capture and
BAM1065 biotinylated detection; R&D,
Minneapolis, MN). These antibodies recognize
epitopes in the globular head of adiponectin
and detect all isoforms. Black 96-well plates
(Maxisorp; Nunc, Rochester, NY) were coated
with the capture antibody and blocked with
0.5% BSA. Plates were then coincubated with
the detection antibody and recombinant
human adiponectin (R&D) or CM aliquots.
After 2 hr, we added streptavidin-conjugated
horseradish peroxidase and a ﬂuorimetric sub-
strate (Quantablue; Pierce, Rockford, IL). We
read fluorescence at 325 nm excitation and
420 nm emission, using a Gemini XPS ﬂuo-
rescent microplate reader (Molecular Devices,
Sunnyvale, CA). The lowest detectable level
was 100 pg/mL. We validated assay parame-
ters against commercial plates from the same
vendor.
Real-time polymerase chain reaction
(PCR). We isolated total RNA from breast,
VIS, and SC adipose tissue, each pooled from
four or ﬁve women, followed by synthesis of
oligo-dT–primed polyA cDNA as previously
described (Hugo et al. 2006). We performed
quantitative real-time PCR on 200 ng of
cDNA using intron-spanning primers for the
various genes listed in Table 1, using Immolase
heat-activated Taq DNA polymerase (Bioline,
Tauton, MA), and SYBR Green I (Invitrogen,
Carlsbad, CA) on a SmartCycler I (Cepheid,
Sunnyvale, CA). Cycle parameters were 96°C
for 6 min followed by 40 cycles of 95°C for
15 sec, 57°C for 15 sec, and 72°C for 25 sec.
We conﬁrmed product purity by melting curve
analysis. Each sample was run three times.
Changes in gene expression were calculated
from the cycle threshold, after correcting for
cDNA amounts using β2 microglubulin
(B2M) expression (Pfafﬂ et al. 2002). Data are
expressed as fold changes over control, which
was arbitrarily defined as gene expression in
VIS tissue.
Data analysis. When appropriate, values
are expressed as the mean ± SE. We performed
statistical analysis using either Student’s t-test or
one-way analysis of variance followed by Fisher
least significant difference post hoc analysis.
p-Values < 0.05 are considered signiﬁcant.
Results
Suppression of adiponectin release from breast
adipose explants by BPA and E2. Both
adiponectin (Martin et al. 2006) and BPA
(Kuruto-Niwa et al. 2007) are detectable in
human breast milk. Therefore, we ﬁrst exam-
ined whether BPA alters adiponectin release
from breast adipose explants obtained from
eight women undergoing breast reduction. As
detailed in Table 2, the average age was
43.6 years, and the average body mass index
(BMI) was 27, with one woman in the obese
category (BMI > 30), four in the overweight
category (BMI = 25–30), and three in the
normal weight range (BMI ≤ 25). Table 2
also demonstrates the high variability of basal
adiponectin release in vitro, which showed no
apparent relationship to either age or BMI.
Figure 1A depicts the suppressive effects of
both BPA and E2 on adiponectin release from
breast explants from one patient, selected as a
representative. E2 showed dose-dependent
Inhibition of adiponectin release by bisphenol A
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Table 1. Human gene-speciﬁc primers for quantitative real-time reverse transcriptase PCR.
Accession Product
Gene no.a Forward primer (5´→3´) Reverse primer (5´→3´) size (bp)
ESR1 NM_000125 CAGGCACATGAGTAACAAAGG CAAGGAATGCGATGAAGTAGAG 195
ESR2 NM_001437 CAGTTATCACATCTGTATGCGG ACTCCATAGTGATATCCCGA 208
ESRRA NM_004451 ACTGCAGGATGAGCTGG TGCACAGAGTCTGAATTGG 185
ESRRB NM_004452 CTGGTGTACGCTGAGGA TACATGGAATCGGAGTTGG 172
ESRRG NM_001438 CATATTCCAGGCTTCTCCA GACAAGTTCATCCTCAAACGA 122
GPR30 NM_001039966 ACGAGACTGTGAAATCCGCAACCA ATCAGGCTGGAGGTGCACTTGGAA 153
B2M NM_004048 GGCATTCCTGAAGCTGAC GAATCTTTGGAGTACGCTGG 114
Primer pairs are all intron-spanning pairs. Abbreviations: ESR1, ERα; ESR2, ERβ; ESRRA, ERRα; ESRRB, ERRβ; ESSRG,
ERRγ (all three transcripts); B2M, β2-microglobulin.
aGenBank accession numbers (National Center for Biotechnology Information 2008).
Table 2. Breast explants by identification number (ID), patient’s age, BMI (kg/m2), and basal in vitro
adiponectin release (Adipo).
ID Age (years) BMI Adipoa
209 51 28.2 77.3
511 30 36.6 53.5
608 57 25.2 8.6
609 40 28.1 23.6
621 23 21.5 39.1
908 57 26.9 10.4
111 58 22.5 44.4
314 33 27.3 75.5
Mean ± SE 43.6 ± 4.9 27.0 ± 1.6 41.6 ± 9.4
ang/100 mg/6 hr.inhibition of adiponectin release, which was
significant (p < 0.05) at all doses except
0.1 nM. On the other hand, BPA generated a
clear U-shaped response, being significantly
suppressive at both the 0.1 and 1 nM doses
but not at higher doses. Figure 1B–D shows
adiponectin release in response to 1 nM BPA,
E2, or ICI in explants from individual
patients. Suppression of adiponectin by BPA
and E2 was signiﬁcant in ﬁve of eight and ﬁve
of six samples tested, respectively. We also
examined several samples for the effects of
1 nM ICI. In this case, three of ﬁve samples
showed signiﬁcant inhibition.
BPA at low doses suppresses adiponectin
release from abdominal SC explants. We next
explored the effects of BPA and E2 on adipose
tissue other than the breast. For that, we
obtained SC abdominal adipose samples from
nine women undergoing abdominoplasty.
Table 3 shows that the average age was
40.3 years (range, 29–45 years). Five patients
had BMI at the normal range, whereas four
were in the overweight category. Similar to
what we observed in breast explants (Table 2),
basal adiponectin release in vitro was highly
variable, ranging from 7.1 ng/100 mg/6 hr in
one patient to 155.2 ng/100 mg/6 hr in
another.
Figure 2A shows the effects of increasing
doses of BPA and E2 on adiponectin release in
an SC abdominal sample from one patient,
selected as a representative. Both compounds
generated U-shaped curves, with BPA signiﬁ-
cantly inhibiting adiponectin at the 0.1, 1, and
10 nM doses, whereas E2 was effective at the 1
and 10 nM doses. Figure 2B–D shows data
from individual patients. BPA at the 1 nM
dose significantly inhibited adiponectin in
eight of nine samples, whereas E2 was effective
only in four of nine samples. We examined the
effect of 1 nM ICI in four samples, only one of
which showed signiﬁcant inhibition.
BPA and E2 exert direct inhibitory effects
on mature adipocytes. In addition to mature
adipocytes, adipose tissue contains pre-
adipocytes, fibroblasts, endothelial cells, and
macrophages, many of which affect the secre-
tory activity of the adipocytes (Fain et al.
2004). Thus, we opted to examine if the
above compounds have a direct or an indirect
effect on adiponectin release. We isolated
mature SC adipocytes from several additional
women undergoing abdominoplasty. Figure 3
illustrates the secretory proﬁle of adiponectin
from a nonobese patient (Figure 3A; 57 years
of age, BMI = 28.8) and an obese patient
(Figure 3B; 54 years of age, BMI = 45.2). BPA
and E2 significantly inhibited adiponectin
release from mature adipocytes at most doses
examined, albeit without exhibiting dose-
dependent effects. ICI at all doses examined
significantly inhibited adiponectin release
(Figure 3B).
BPA and E2 inhibit adiponectin release
by SC and VIS explants from morbidly obese
patients. To examine whether adiponectin
responsiveness to BPA or E2 is inﬂuenced by
obesity, we obtained matched VIS (omental)
and SC adipose samples from several mor-
bidly obese patients undergoing gastric bypass
surgery. Figure 4A shows results with tissue
explants from an extremely obese woman
(29 years of age, BMI = 84.5). To compare
Hugo et al.
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Figure 2. Suppression of adiponectin release from abdominal SC adipose explants by BPA, E2, and ICI.
(A) Typical dose response by explants from one patient; each value is the mean ± SE of six determinations.
(B–D) Responses of explants from nine women to 1 nM BPA (B), E2 (C), or ICI (D), illustrating variation
among patients in both adiponectin secretion and responsiveness to the test compounds.
*p < 0.05 compared with control.
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Table 3. Abdominal SC explants by identiﬁcation number (ID), patient’s age, BMI (kg/m2), and basal in vitro
adiponectin release (Adipo).
ID Age (years) BMI Adipoa
327 37 24.8 40.7
323 42 24.8 70.0
410 44 24.4 44.7
421 45 20.9 62.5
713 45 21.4 155.2
719 44 28.3 7.1
803 44 26.1 28.2
817 29 26.3 11.6
314 33 27.3 40.4
Mean ± SE 40.3 ± 2.0 24.9 ± 0.8 51.2 ± 14.7
ang/100 mg/6 hr.
Figure 1. Suppression of adiponectin release from breast adipose explants by BPA, E2, and ICI. (A) Typical
dose response by explants from one patient; each value is the mean ± SE of six determinations. (B–D)
Responses of explants from eight women to 1 nM BPA (B), E2 (C), or ICI (D), illustrating variation among
patients in both basal adiponectin secretion (see also Table 2) and responsiveness to the test compounds. 
*p < 0.05 compared with control.
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908 608the rate of adiponectin release over time, in
this case we present the data as picograms
adiponectin/100 mg/hr. Basal adiponectin
release from SC explants showed a time-
dependent decline, which was not observed in
VIS explants. The time-dependent decline in
adiponectin was not due to loss of tissue via-
bility, as determined by the use of a fluores-
cent Resazurin reduction assay (data not
shown). BPA at 1 nM signiﬁcantly inhibited
adiponectin release from SC explants by 50%
at 6 hr and 23% at 24 hr, whereas inhibition
by E2 did not reach statistical significance.
We saw a more profound inhibition of 65%
and 50% by both BPA and E2 in VIS
explants at 6 and 24 hr, respectively.
Matched VIS (omental) and SC explants,
obtained from a morbidly obese man (54 years
of age, BMI = 45.2), were incubated for 6 hr
with different doses of BPA, E2, and ICI.
Figure 4B shows that both BPA and E2 were
effective in suppressing adiponectin release
from SC explants at 0.1 and 1 nM. E2 at 1 and
10 nM significantly suppressed adiponectin
release from VIS explants, whereas BPA had no
effect at all doses examined. Surprisingly, 1 nM
ICI suppressed adiponectin release from VIS
explants by as much as 70% but had no effect
on SC explants.
Comparison of receptor expression in
breast, VIS (omental), and SC adipose tissue.
We next examined breast, VIS, and SC adi-
pose tissue, each pooled from four or five
women, for expression of putative receptors
that may mediate the actions of BPA and/or
E2. Figure 5A shows relative mRNA expres-
sion of ERα, ERβ, GPR30, ERRα, ERRβ, and
ERRγ in breast and SC adipose tissue, com-
pared with VIS adipose tissue, which was used
as a reference. All six receptors were more
highly expressed in breast adipose tissue (from
1.8- to 7.3-fold) than VIS adipose tissue. The
expression of GPR30 and ERRα was approxi-
mately the same in VIS and SC adipose tissue
(1.4- to 1.5-fold), whereas ERα, ERβ, and
ERRβ were moderately higher (from 1.7- to
2.1-fold) in SC tissue. Notably, expression of
ERRγ was much lower (0.3-fold) in SC than
in VIS adipose tissue.
Figure 5B shows the relative abundance of
mRNA levels of the above receptors in VIS
adipose tissue, with expression of the most
abundant receptor (ERα) presented as 100%.
Expression levels of ERβ and ERRγ were 50%
and 20%, respectively, relative to ERα. On
the other hand, expression of ERRα, ERRβ,
and GPR30 was < 1% of ERα, indicating a
signiﬁcantly lower abundance.
Discussion
This study provides the first evidence that
BPA at environmentally relevant doses
inhibits a key adipokine that protects humans
from the sequelae of the metabolic syndrome.
BPA at low nanomolar concentrations sup-
pressed adiponectin release from human adi-
pose tissue explants as well as from isolated
mature adipocytes. Despite a substantial vari-
ability among patients, BPA was as effective,
and often more effective, than equimolar con-
centrations of E2. The suppressive effects of
BPA were not conﬁned to one adipose tissue
type but were present in all depots examined:
breast, SC, and VIS. We also report for the
first time similar mRNA expression levels of
ERα, ERβ, and ERRγ in VIS adipose tissue.
The expression of ERα, GPR30, ERRα, and
ERRγ was higher in breast than in either VIS
or SC fat. The relative expression of these
receptors in VIS adipose tissue was ERα >
ERβ > ERRγ >>> GPR30 = ERRα = ERRβ.
The role of any of these receptors in mediat-
ing the suppressive actions of BPA or E2 on
adiponectin release remains to be determined.
Inhibition of adiponectin release by bisphenol A
Environmental Health Perspectives • VOLUME 116 | NUMBER 12 | December 2008 1645
Figure 3. BPA and E2 suppress adiponectin release from mature abdominal SC adipocytes from a non-
obese woman (A) and an obese woman (B). (A) Effect of treatment with increasing doses of BPA or E2.
(B) Effect of treatment with increasing doses of BPA, E2, and ICI. Each value is  the mean ± SE of four
determinations.
*p < 0.05 compared with control.
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Figure 4. Effects of BPA, E2, or ICI on adiponectin release. (A) Time-dependent effect of 1 nM BPA or E2 on
adiponectin release from SC and VIS (omental) adipose tissue explants from a morbidly obese woman.
(B) Effect of treatment with increasing doses of BPA and E2, as well as 1 nM ICI, on adiponectin release
from matched abdominal SC and VIS (omental) adipose tissue explants from a morbidly obese man. Each
value is the mean ± SE of six determinations. 
*p < 0.05 compared with control.
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SC VISPrevious studies on direct actions of BPA
on rodent adipocytes have used very high
doses. Sakurai et al. (2004) reported that BPA
stimulated insulin-dependent glucose uptake
and increased expression of the glucose trans-
porter (Glut4) in 3T3-F442A murine adipo-
cytes, whereas E2 was ineffective and ICI did
not antagonize BPA. However, only the high-
est BPA dose (100 µM) was effective. Masuno
et al. (2002, 2005) reported that BPA acceler-
ated adipogenesis in 3T3-L1 adipocytes and
increased the activity of lipoprotein lipase.
Again, BPA was active only at doses of
> 80 µM. These data should be interpreted
with caution, given the nonlinear dose
response of BPA and the potential toxic, or
near toxic, levels of BPA. A U-shaped dose–
response curve is well recognized for many
hormones and toxic compounds, but there is
no ready explanation for this phenomenon
(Calabrese and Baldwin 2001).
To support the premise that BPA has
adverse metabolic effects in humans, it is
essential to study its actions on human tissues.
Whereas the value of live rodents and murine
adipocyte cell lines as experimental models is
undisputed, adipocyte biology is sufficiently
different between rodents and humans to war-
rant prudence (Ben Jonathan et al. 2008). For
example, the regional distribution of fat
depots, their cellular composition (e.g., brown
vs. white fat, inﬁltration by macrophages), and
the regulation of resistin, agouti protein,
adipsin, and adrenergic receptors are dissimilar
in rodents and humans. Intrinsic differences
between the species are also exempliﬁed by the
suppression of adiponectin expression in
3T3-L1 cells by insulin but its increase in
response to insulin in isolated human adipose
tissue (Whitehead et al. 2006).
Basal adiponectin release in vitro and its
responsiveness to BPA or E2 were highly vari-
able among patients. This variability results
from the combined effects of genetic, nutri-
tional, and hormonal factors, as well as the
state of obesity, clinical conditions, and history
of drug use. Because all but one of the patients
were women, we did not determine the effect
of sex. Serum adiponectin levels are moderately
higher in women than in men, but hormone
replacement therapy does not alter adiponectin
release in either pre- or postmenopausal
women (Sieminska et al. 2005). The difference
in circulating adiponectin between sexes is
believed to be due to its suppression by andro-
gens, as supported by an inverse relationship
between serum testosterone and adiponectin
levels during puberty in men (Andersen et al.
2007). An inadvertent exposure of men to
exogenous estrogen-like compounds such as
BPA may cause additional suppression of
adiponectin, leading to potential harmful con-
sequences. The same concern is extended to
prepubertal girls and postmenopausal women
with low serum estrogen levels.
Given the relatively small sample size in
each category and the observed variability, our
data do not lend themselves to deﬁnitive con-
clusions with regard to the relative effectiveness
of BPA versus E2, which adipose depot is more
responsive, whether obesity alters tissue respon-
siveness, or the potential effects of age.
Therefore, we highlight only the general trends
observed in this study. For example, BPA, E2,
and ICI appear to display similar efficacy in
suppressing adiponectin release from breast
explants, whereas BPA was more effective than
E2 or ICI in SC adipose explants. In one obese
woman, BPA was more effective in suppressing
adiponectin from VIS than from SC explants,
whereas the reverse was true in an obese man
(Figure 4). Recruitment of a larger number of
patients will be most helpful in sorting out the
effects of age, sex, obesity, or clinical condi-
tions on adipose tissue responsiveness to BPA
and/or E2.
Most research to date on the biological
actions of estrogens has focused on ERα.
Studies with knockout mice revealed that dele-
tion of ERα causes a more severe phenotype
than deletion of ERβ (Couse and Korach
1999). With the exception of few tissues such
as the ovary, prostate, and certain brain areas,
ERα is more highly expressed than ERβ.
Therefore, it was unexpected that human VIS
fat expressed similar mRNA levels of both
receptors. Using real-time PCR, others
reported predominance of ERα over ERβ in
isolated mature adipocytes, although ERβ
expression was higher in adipocytes from
women than from men (Dieudonne et al.
2004). Given adipose tissue heterogeneity, it is
difficult to compare receptor expression in
whole adipose tissue, as we used in our studies,
with that in isolated adipocytes. In addition, at
least four different ERβ subtypes are expressed
in human adipose tissue (Pedersen et al.
2001), with our primers detecting only the
common isoform.
The finding that both BPA and E2 sup-
press adiponectin release does not constitute a
proof that they act by the same mechanism.
In fact, their equipotency strongly suggests
involvement of receptors other than classical
ERs. The effects of ICI further confound the
issue. In these studies, ICI at low doses either
suppressed or had no effect on adiponectin
release. In samples pretreated with ICI before
exposure to BPA or E2, we observed neither
blockade of suppression nor additive effects
(data not shown). Thus, in terms of the con-
trol of adiponectin release, ICI does not
behave as a typical ERα/ERβ antagonist. The
suppressive effect of ICI also differentiate the
putative receptor in human adipose tissue
from the ncmER reported by Alonso-
Magdalena et al. (2005) that is activated
rapidly and is unresponsive to ICI. Although
searching for potential mechanisms for the
actions of BPA and E2, we examined pub-
lished values of their binding affinity to sev-
eral putative receptors. Although BPA has a
lower median effective concentration (EC50)
for ERβ than for ERα (Kuiper et al. 1998), it
is still in the micromolar range, compared
with a low nanomolar range for E2. On the
other hand, the EC50 for BPA for GPR30 is
630 nM (Thomas and Dong 2006) and is as
low as 8.9 nM for ERRγ (Okada et al. 2008).
GPR30 is a seven-transmembrane receptor
that increases the activity of second messengers
such as adenylate cyclase and mitogen-acti-
vated protein kinase in response to E2 in ER-
negative breast cancer cell lines (Filardo and
Thomas 2005). Notably, the ER antagonist
ICI functions as a GPR30 agonist. Our data
are the ﬁrst to show expression of GPR30 in
human adipose tissue, albeit at very low abun-
dance compared with either ERα or ERβ
(Figure 5). Another potential candidate is
ERRγ, whose expression level in VIS adipose
tissue was 4- to 5-fold lower than that of ERα
and ERβ. The ERRs are orphan nuclear recep-
tors that are constitutively active and do not
bind estrogens (Ariazi and Jordan 2006). ERRγ
is expressed in a tissue-speciﬁc manner (Heard
et al. 2000), but little is known about its
biological functions. Future studies should
Hugo et al.
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Figure 5. Depot-speciﬁc differences in the expression of putative receptors that may mediate the action of
BPA or E2, as determined by real-time reverse transcriptase PCR. (A) Differences in expression of ERα,
ERβ, GPR30, ERRα, ERRβ, and ERRγ in SC and breast (BR) adipose tissue calculated as fold change
(shown above bars) relative to VIS adipose tissue. (B) Relative abundance of the above receptors in VIS
adipose tissue compared with ERα expression.
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confirm expression of these receptors at the
protein level and then use small interfering
RNA to determine the consequences of recep-
tor knockdown on the suppressive effects of E2
or BPA on adiponectin release. It would also
be of interest to examine whether BPA at low
doses affects adipogenesis, lipogenesis/lipolysis,
or the release of other adipokines.
Conclusion
The growing interest by scientists and the
public alike in BPA has placed this com-
pound at the center of the debate over poten-
tial adverse effects of man-made chemicals
found in the environment on fetal/neonatal
development, reproductive fecundity, meta-
bolic homeostasis, and carcinogenesis. Yet,
attribution of such actions to BPA has been
controversial. Differences of opinion and dis-
agreements over data interpretation underlie
the inability of several expert panels, con-
vened periodically since 1999, to convince
regulatory agencies that BPA poses hazards to
human health. There is a growing recognition
that the roles of genetic predisposition and
environmental factors in the epidemic of obe-
sity and related diseases should not be
ignored. Given the endurance of BPA in the
environment, its presence in serum from
humans worldwide, and the suppression of
adiponectin release at nanomolar concentra-
tions, BPA may indeed be the bona fide
endocrine disruptor that adversely affects
metabolic homeostasis and its manifestations.
REFERENCES
Alonso-Magdalena P, Laribi O, Ropero AB, Fuentes E, Ripoll C,
Soria B, et al. 2005. Low doses of bisphenol A and diethyl-
stilbestrol impair Ca2+ signals in pancreatic alpha-cells
through a nonclassical membrane estrogen receptor
within intact islets of Langerhans. Environ Health Perspect
113:969–977.
Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal
A. 2006. The estrogenic effect of bisphenol A disrupts
pancreatic beta-cell function in vivo and induces insulin
resistance. Environ Health Perspect 114:106–112.
Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A.
2007. Gender differences of oligomers and total adiponectin
during puberty: a cross-sectional study of 859 Danish
school children. J Clin Endocrinol Metab 92:1857–1862.
Ariazi EA, Jordan VC. 2006. Estrogen-related receptors as
emerging targets in cancer and metabolic disorders. Curr
Top Med Chem 6:203–215.
Ben Jonathan N, LaPensee CR, LaPensee EW. 2008. What can
we learn from rodents about prolactin in humans? Endocr
Rev 29:1–41.
Calabrese EJ, Baldwin LA. 2001. Hormesis: U-shaped dose
responses and their centrality in toxicology. Trends
Pharmacol Sci 22:285–291.
Couse JF, Korach KS. 1999. Estrogen receptor null mice: what
have we learned and where will they lead us? Endocr Rev
20:358–417.
Dieudonne MN, Leneveu MC, Giudicelli Y, Pecquery R. 2004.
Evidence for functional estrogen receptors alpha and beta
in human adipose cells: regional speciﬁcities and regula-
tion by estrogens. Am J Physiol Cell Physiol 286:C655–C661.
Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. 2004.
Comparison of the release of adipokines by adipose tissue,
adipose tissue matrix, and adipocytes from visceral and
subcutaneous abdominal adipose tissues of obese humans.
Endocrinology 145:2273–2282.
Fernandez MF, Arrebola JP, Taoufiki J, Navalon A,
Ballesteros O, Pulgar R, et al. 2007. Bisphenol-A and chlo-
rinated derivatives in adipose tissue of women. Reprod
Toxicol 24(2):259–264.
Filardo EJ, Thomas P. 2005. GPR30: a seven-transmembrane-
spanning estrogen receptor that triggers EGF release.
Trends Endocrinol Metab 16:362–367.
Heard DJ, Norby PL, Holloway J, Vissing H. 2000. Human ERRγ, a
third member of the estrogen receptor-related receptor
(ERR) subfamily of orphan nuclear receptors: tissue-speciﬁc
isoforms are expressed during development and in the adult.
Mol Endocrinol 14:382–392.
Heindel JJ. 2003. Endocrine disruptors and the obesity epidemic.
Toxicol Sci 76:247–249.
Hugo ER, Brandebourg TD, Comstock CE, Gersin KS, Sussman JJ,
Ben-Jonathan N. 2006. LS14: a novel human adipocyte cell
line that produces prolactin. Endocrinology 147:306–313.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K.
2006. Adiponectin and adiponectin receptors in insulin
resistance, diabetes, and the metabolic syndrome. J Clin
Invest 116:1784–1792.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van
der Saag PT, et al. 1998. Interaction of estrogenic chemi-
cals and phytoestrogens with estrogen receptor beta.
Endocrinology 139:4252–4263.
Kuruto-Niwa R, Tateoka Y, Usuki Y, Nozawa R. 2007. Measure-
ment of bisphenol A concentrations in human colostrum.
Chemosphere 66:1160–1164.
Le HH, Carlson EM, Chua JP, Belcher SM. 2008. Bisphenol A is
released from polycarbonate drinking bottles and mimics
the neurotoxic actions of estrogen in developing cerebellar
neurons. Toxicol Lett 176:149–156.
Martin LJ, Woo JG, Geraghty SR, Altaye M, Davidson BS,
Banach W et al. 2006. Adiponectin is present in human
milk and is associated with maternal factors. Am J Clin
Nutr 83:1106–1111.
Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K. 2005.
Bisphenol A accelerates terminal differentiation of 3T3-L1
cells into adipocytes through the phosphatidylinositol
3-kinase pathway. Toxicol Sci 84:319–327.
Masuno H, Kidani T, Sekiya K, Sakayama K, Shiosaka T,
Yamamoto H, et al. 2002. Bisphenol A in combination with
insulin can accelerate the conversion of 3T3-L1 ﬁbroblasts
to adipocytes. J Lipid Res 43:676–684.
McFarland-Mancini M, Hugo E, Loftus J, Ben Jonathan N. 2006.
Induction of prolactin expression and release in human
preadipocytes by cAMP activating ligands. Biochem
Biophys Res Commun 344:9–16.
National Center for Biotechnology Information. 2008. GenBank
Overview. Available: http://www.ncbi.nlm.nih.gov/Genbank/
[accessed 17 October 2008].
Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. 2007.
Perinatal exposure to environmental estrogens and the
development of obesity. Mol Nutr Food Res 51:912–917.
Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A,
Shimohigashi Y. 2008. Direct evidence revealing structural
elements essential for the high binding ability of
bisphenol A to human estrogen-related receptor-γ. Environ
Health Perspect 116:32–38.
Pedersen SB, Bruun JM, Hube F, Kristensen K, Hauner H,
Richelsen B. 2001. Demonstration of estrogen receptor sub-
types alpha and beta in human adipose tissue: inﬂuences of
adipose cell differentiation and fat depot localization. Mol
Cell Endocrinol 182:27–37.
Pfaffl MW, Horgan GW, Dempfle L. 2002. Relative expression
software tool (REST) for group-wise comparison and sta-
tistical analysis of relative expression results in real-time
PCR. Nucleic Acids Res 30:e36.
Ritchie SA, Connell JM. 2007. The link between abdominal obe-
sity, metabolic syndrome and cardiovascular disease.
Nutr Metab Cardiovasc Dis 17:319–326.
Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, McDonnell D.
2002. Problems for risk assessment of endocrine-active
estrogenic compounds. Environ Health Perspect 110(suppl
6):925–929.
Sakurai K, Kawazuma M, Adachi T, Harigaya T, Saito Y,
Hashimoto N, et al. 2004. Bisphenol A affects glucose
transport in mouse 3T3-F442A adipocytes. Br J Pharmacol
141:209–214.
Sieminska L, Wojciechowska C, Niedziolka D, Marek B, Kos-
Kudla B, Kajdaniuk D, et al. 2005. Effect of postmenopause
and hormone replacement therapy on serum adiponectin
levels. Metabolism 54:1610–1614.
Thomas P, Dong J. 2006. Binding and activation of the seven-
transmembrane estrogen receptor GPR30 by environmen-
tal estrogens: a potential novel mechanism of endocrine
disruption. J Steroid Biochem Mol Biol 102:175–179.
Trujillo ME, Scherer PE. 2005. Adiponectin—journey from an
adipocyte secretory protein to biomarker of the metabolic
syndrome. J Intern Med 257:167–175.
Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC. 2005.
Signaling from the membrane via membrane estrogen
receptor-alpha: estrogens, xenoestrogens, and phyto-
estrogens. Steroids 70:364–371.
Welshons WV, Nagel SC, Vom Saal FS. 2006. Large effects from
small exposures. III. Endocrine mechanisms mediating
effects of bisphenol A at levels of human exposure.
Endocrinology 147:S56–S69.
Whitehead JP, Richards AA, Hickman IJ, Macdonald GA,
Prins JB. 2006. Adiponectin—a key adipokine in the meta-
bolic syndrome. Diabetes Obes Metab 8:264–280.